These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8545353)

  • 1. [Immunotherapy in metastatic cancer of the kidney].
    Escudier B
    Presse Med; 1995 Oct; 24(32):1504-6. PubMed ID: 8545353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of immunotherapy in metastatic cancer of the kidney].
    Thiounn N
    J Urol (Paris); 1994; 100(5):231-7. PubMed ID: 7730669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapy of renal cell carcinoma: results from current phase-III-trials].
    Doehn C; Jocham D
    Aktuelle Urol; 2004 Apr; 35(2):121-9. PubMed ID: 15146376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
    Linehan WM; Walther MM; Alexander RB; Rosenberg SA
    Semin Urol; 1993 Feb; 11(1):41-3. PubMed ID: 8465127
    [No Abstract]   [Full Text] [Related]  

  • 5. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B; Young M; Ho KJ
    Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA; Pierce WC; Belldegrun A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in metastatic renal cell carcinoma.
    Rohrmann K; Staehler M; Haseke N; Bachmann A; Stief CG; Siebels M
    World J Urol; 2005 Jul; 23(3):196-201. PubMed ID: 15806434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferons and interleukins in metastatic renal cell carcinoma.
    Choudhury M; Efros M; Mittelman A
    Urology; 1993 Jan; 41(1 Suppl):67-72. PubMed ID: 7678365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
    Pantuck AJ; Belldegrun AS; Figlin RA
    N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
    [No Abstract]   [Full Text] [Related]  

  • 11. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma.
    Fleischmann JD; Kim B
    J Urol; 1991 May; 145(5):938-41. PubMed ID: 2016805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA; Benyunes MC; Bianco JA; Fefer A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer immunotherapy using tumor-infiltrating lymphocytes.
    Figlin RA
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil.
    Hofmockel G; Langer W; Theiss M; Gruss A; Frohmüller HG
    J Urol; 1996 Jul; 156(1):18-21. PubMed ID: 8648791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.
    Belldegrun A; Pierce W; Kaboo R; Tso CL; Shau H; Turcillo P; Moldawer N; Golub S; deKernion J; Figlin R
    J Urol; 1993 Nov; 150(5 Pt 1):1384-90. PubMed ID: 8411405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.
    Kuebler JP; Whitehead RP; Ward DL; Hemstreet GP; Bradley EC
    J Urol; 1993 Sep; 150(3):814-20. PubMed ID: 8345590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon alpha for the treatment of advanced renal cancer.
    Ravaud A; Dilhuydy MS
    Expert Opin Biol Ther; 2005 Jun; 5(6):749-62. PubMed ID: 15952906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
    Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in immune-based therapies of renal cell carcinoma.
    Lam JS; Belldegrun AS; Figlin RA
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.